Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.
| Original language | English |
|---|---|
| Pages (from-to) | 239-256 |
| Number of pages | 18 |
| Journal | Diabetes Therapy |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 26 2015 |
Fingerprint
Keywords
- GLP-1 RAs
- Glucagon-like peptide-1 receptor agonists
- Incretin
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. / Uccellatore, Annachiara; Genovese, Stefano; Dicembrini, Ilaria; Mannucci, Edoardo; Ceriello, Antonio.
In: Diabetes Therapy, Vol. 6, No. 3, 26.09.2015, p. 239-256.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
AU - Uccellatore, Annachiara
AU - Genovese, Stefano
AU - Dicembrini, Ilaria
AU - Mannucci, Edoardo
AU - Ceriello, Antonio
PY - 2015/9/26
Y1 - 2015/9/26
N2 - Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.
AB - Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.
KW - GLP-1 RAs
KW - Glucagon-like peptide-1 receptor agonists
KW - Incretin
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84942306927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942306927&partnerID=8YFLogxK
U2 - 10.1007/s13300-015-0127-x
DO - 10.1007/s13300-015-0127-x
M3 - Article
AN - SCOPUS:84942306927
VL - 6
SP - 239
EP - 256
JO - Diabetes Therapy
JF - Diabetes Therapy
SN - 1869-6953
IS - 3
ER -